For the relief of allergic rhinitis, including hay fever
Order Almus products through the Alliance Healthcare Portal, AH Direct, your PMR or call: 0330 100 0448
PIP
Product Description
RRP 4231304 Almus Allergy Relief 8mg Capsule £5.25
Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at:
https://mhraproducts4853.blob.core.windows.net/ docs/498def6a7400ff 9e87cf3470e3b73a7b1a4c89ed. Essential Information. Name of Product: Almus Allergy Relief 8mg Capsules, hard. Active Ingredient: 8mg acrivastine. Excipients: 173.0 mg lactose monohydrate. Other excipients: Sodium starch glycolate, Magnesium stearate, Titanium dioxide, Gelatin, Purifi ed water. Indications: Acrivastine is indicated for symptomatic relief of allergic rhinitis, including hay fever. Acrivastine is also indicated for chronic idiopathic urticaria. Dosage: For oral use. Adults and adolescents 12 years – 65 years: One 8 mg capsule, as necessary up to three times a day. Use in the Elderly (over 65): As yet, no specifi c studies have been carried out in the elderly. Until further information is available, Acrivastine should not be given to elderly patients. Paediatric population: The safety and effi cacy of Brown & Burk Allergy relief in children under 12 years of age has not yet been established. Renal dysfunction: This product is contraindicated in patients with severe renal impairment. Contraindications: Acrivastine is contraindicated in individuals with known hypersensitivity to acrivastine, triprolidine or to any of the excipients listed. Renal excretion is the principal route of elimination of acrivastine. Until specifi c studies have been carried out acrivastine should not be given to patients with signifi cant renal impairment. Special warnings and precautions: Concomitant administration of acrivastine with CNS depressants, including alcohol, sedatives, and tranquilizers, may produce additional impairment in mental alertness in some individuals. Patients with renal impairment should consult with a physician before use. This product may cause drowsiness. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase defi ciency or glucose-galactose malabsorption should not take this medicine. Interactions: It is usual to advise patients not to undertake tasks requiring mental alertness whilst under the infl uence of alcohol and other CNS depressants. Concomitant administration of acrivastine may, in some individuals, produce additional impairment. There are no data to demonstrate an interaction between acrivastine and ketoconazole, erythromycin or grapefruit juice. However, due to known interactions between these compounds and other non-sedating antihistamines, caution is advised. Pregnancy and lactation: No information is available on the eff ects of administration of acrivastine during human pregnancy or lactation. Acrivastine, like most medicines, should not be used during pregnancy or lactation unless the potential benefi t of treatment to the mother outweighs any possible risk to the developing foetus/nursing infant. Fertility Systemic administration of acrivastine in animal reproductive studies did not produce embryotoxic or teratogenic eff ects and did not impair fertility. Pregnancy There are no adequate and well-controlled studies in pregnant women. Lactation: There is no information on the levels of acrivastine which may appear in human breast milk after administration of acrivastine. Eff ects on ability to drive or use machines: Acrivastine may cause dizziness and somnolence. As there is individual variation in response to all medication, it is sensible to caution all patients about engaging in activities requiring mental alertness, such as driving a car or operating machinery, until patients are familiar with their own response to the drug. Undesirable eff ects: Somnolence, dizziness, dry mouth. Overdose: Symptoms: Drowsiness, restlessness, hyperactivity and tachycardia have been reported in overdose. When the recommended therapeutic dose has been exceeded, acrivastine has been found to impair the ability to drive. This eff ect is related to the amount of acrivastine taken beyond the recommended maximum daily dosage. Management: Appropriate supportive therapy, including activated charcoal should be initiated if indicated. Special precautions for storage: Do not store above 30°C. Store in the original package. Shelf life is 3 years. Classifi cation: P MA Number: PL 25298/0231. Authorised under a UKMA(GB). MA Holder: Brown & Burk UK Ltd, 5, Marryat Close, Hounslow West, Middlesex, TW4 5DQ, UK. Adverse events should be reported. Reporting forms and information can be found at:
www.mhra.gov.uk/yellowcard. Please consult the summary of product characteristics (SmPC) before recommending. Keep medicines out of the sight and reach of children. Date of preparation: April 2025
Copyright © 2026 Alliance Unichem IP Limited
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
